| Medicines/Item |
Section |
Status |
Link Name / Link URL |
| Dupilumab injection |
13.05.03 |
Formulary
|
NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis |
| Abatacept injection |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (NHSE) |
| Abatacept injection |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Abemaciclib tabs |
08.01.05 |
Formulary
|
NICE TA563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Abemaciclib tabs |
08.01.05 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (CDF) |
| Abiraterone tabs |
08.03.04.02 |
Formulary
|
NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen |
| Abiraterone tabs |
08.03.04.02 |
Formulary
|
NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa |
| Adalimumab injection |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Adalimumab injection |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Adalimumab injection |
10.01.03 |
Formulary
|
NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
| Adalimumab injection |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (CCG) |
| Adalimumab injection |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Adalimumab injection |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Adalimumab injection |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Adalimumab injection |
13.05.03 |
Formulary
|
NICE TA146: Adalimumab for the treatment of adults with psoriasis |
| Adalimumab injection |
11.99.99.99 |
Formulary
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Adefovir dipivoxil tablets |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA96 |
| Adefovir dipivoxil tablets |
05.03.03.01 |
Formulary
|
NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a |
| Afatinib tabs |
08.01.05 |
Formulary
|
NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer |
| Aflibercept |
08.01.05 |
Non Formulary
|
NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy |
| Aflibercept intravitreal injection |
11.08.02 |
Formulary
|
NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion |
| Aflibercept intravitreal injection |
11.08.02 |
Formulary
|
NICE TA294: Macular degeneration (wet age-related) - aflibercept |
| Aflibercept intravitreal injection |
11.08.02 |
Formulary
|
NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion |
| Aflibercept intravitreal injection |
11.08.02 |
Formulary
|
NICE TA486: Aflibercept for treating choroidal neovascularisation |
| Aflibercept intravitreal injection |
11.08.02 |
Formulary
|
NICE TA346: Aflibercept for treating diabetic macular oedema |
| Alectinib caps |
08.01.05 |
Formulary
|
NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer |
| Alemtuzumab |
08.02.03 |
Non Formulary
|
NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
| Alemtuzumab injection |
08.02.03 |
Formulary
|
NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
| Alirocumab injection |
02.12 |
Restricted Use
|
NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Alitretinoin caps |
13.05.01 |
Formulary
|
NICE TA177: Eczema (chronic) - alitretinoin |
| Alteplase injection |
02.10.02 |
Formulary
|
NICE TA264: Ischaemic stroke (acute) - alteplase |
| Amantadine |
04.09.01 |
Non Formulary
|
Amantadine, oseltamivir and zanamivir for the treatment of influenza |
| Amantadine caps, syrup |
04.09.01 |
Formulary
|
NICE CG186: Multiple sclerosis in adults: management |
| Anti-D (Rh0) Immunoglobulin injection |
14.05.03 |
Formulary
|
NICE TA156: Anti-D in pregnant women |
| Apixaban tabs |
02.08.02 |
Formulary
|
NICE TA341: Apixaban for treatment and secondary prevention of DVT and/or PE |
| Apixaban tabs |
02.08.02 |
Formulary
|
NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery |
| Apixaban tabs |
02.08.02 |
Formulary
|
NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban |
| Apremilast tabs |
13.05.03 |
Formulary
|
NICE TA419: Apremilast for treating moderate to severe plaque psoriasis |
| Apremilast tabs |
13.05.03 |
Formulary
|
NICE TA433: Apremilast for treating active psoriatic arthritis |
| Aripiprazole tabs |
04.02.01 |
Restricted Use
|
NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder |
| Aripiprazole tabs |
04.02.01 |
Restricted Use
|
NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years |
| Arsenic trioxide injection |
08.01.05 |
Formulary
|
NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia |
| Aspirin (antiplatelet) tabs |
02.09 |
Formulary
|
NICE NG133: Hypertension in pregnancy: diagnosis and management |
| Atezolizumab injection |
08.01.05 |
Formulary
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer |
| Atezolizumab injection |
08.01.05 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab injection |
08.01.05 |
Formulary
|
NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy |
| Atezolizumab injection |
08.01.05 |
Formulary
|
NICE TA584: Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer |
| Atezolizumab injection |
08.01.05 |
Formulary
|
NICE TA638: Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancer |
| Atezolizumab injection |
08.01.05 |
Formulary
|
NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF) |
| Atezolizumab injection |
08.01.05 |
Formulary
|
NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy |
| Avatrombopag tabs |
09.01.04 |
Formulary
|
NICE TA626: Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Avelumab injection |
08.01.05 |
Formulary
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma |
| Avelumab injection |
08.01.05 |
Formulary
|
NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma (CDF) |
| Axicabtagene ciloleucel cells dispersion for infusion |
08.01.05 |
Formulary
|
NICE TA559: Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies (CDF) |
| Axitinib tabs |
08.01.05 |
Formulary
|
NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment |
| Axitinib tabs |
08.01.05 |
Formulary
|
NICE TA645: Avelumab with axitinib for untreated advanced renal cell carcinoma (CDF) |
| Azacitidine injection |
08.01.03 |
Restricted Use
|
NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia |
| Azacitidine injection |
08.01.03 |
Non Formulary
|
NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts |
| Baricitinib tabs |
10.01.03 |
Formulary
|
NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis |
| Basiliximab injection |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Basiliximab injection |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Belimumab injection |
10.01.03 |
Restricted Use
|
NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus |
| Bendamustine injection |
08.01.01 |
Formulary
|
NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia |
| Bendamustine injection |
08.01.01 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Bendamustine injection |
08.01.01 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Benralizumab injection |
03.04.02 |
Formulary
|
NICE TA565: Benralizumab for treating severe eosinophilic asthma |
| Binimetinib tabs |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Bivalirudin injection |
02.08.01 |
Formulary
|
NICE TA230 : Bivalirudin for the treatment of STEMI, 2011 |
| Bivalirudin injection |
02.08.01 |
Formulary
|
NICE CG94: Unstable angina and NSTEMI |
| Blinatumomab injection |
08.02.03 |
Formulary
|
NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia |
| Blinatumomab injection |
08.02.03 |
Formulary
|
NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity |
| Bortezomib injection |
08.01.05 |
Formulary
|
NICE TA370: Bortezomib for previously untreated mantle cell lymphoma |
| Bortezomib injection |
08.01.05 |
Formulary
|
NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma |
| Bortezomib injection |
08.01.05 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Bortezomib injection |
08.01.05 |
Formulary
|
NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation |
| Bortezomib injection |
08.01.05 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (CDF) |
| Bosutinib tabs |
08.01.05 |
Formulary
|
NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia |
| Botulinum toxin A |
01.02 |
Formulary
|
NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea |
| Botulinum Toxin Type A |
04.07.04.02 |
Restricted Use
|
NICE TA260: Botox for migraine prophylaxis |
| Brentuximab injection |
08.01.05 |
Formulary
|
NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma |
| Brentuximab injection |
08.01.05 |
Formulary
|
NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma |
| Brentuximab injection |
08.01.05 |
Formulary
|
NICE TA641: Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma |
| Brentuximab injection |
08.01.05 |
Formulary
|
NICE TA577: Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma |
| Brigatinib tabs |
08.01.05 |
Formulary
|
NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib |
| Brodalumab injection |
13.05.03 |
Formulary
|
NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis |
| Cabazitaxel injection |
08.01.05 |
Formulary
|
NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel |
| Cabozantinib caps |
08.01.05 |
Formulary
|
NICE TA516: Cabozantinib for treating medullary thyroid cancer |
| Cabozantinib tablets |
08.01.05 |
Formulary
|
NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma |
| Cabozantinib tablets |
08.01.05 |
Formulary
|
NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma |
| Canagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes |
| Canagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Cannabidiol solution |
04.06 |
Formulary
|
NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome |
| Cannabidiol solution |
04.06 |
Formulary
|
NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome |
| Capecitabine tabs |
08.01.03 |
Formulary
|
NICE TA191: Capecitabine for the treatment of advanced gastric cancer |
| Capecitabine tabs |
08.01.03 |
Formulary
|
NICE CG81: Advanced breast cancer: diagnosis and treatment |
| Capecitabine tabs |
08.01.03 |
Formulary
|
NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer |
| Capecitabine tabs |
08.01.03 |
Formulary
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer |
| Carfilzomib injection |
08.01.05 |
Formulary
|
NICE TA457: Carfilzomib for previously treated multiple myeloma |
| Carmustine |
08.01.01 |
Non Formulary
|
NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide |
| Carmustine implant |
08.01.01 |
Formulary
|
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma |
| Cemiplimab injection |
08.01.05 |
Formulary
|
NICE TA592: Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma (CDF) |
| Cenegermin drops |
11.08 |
Non Formulary
|
NICE TA532: Cenegermin for treating neurotrophic keratitis |
| Ceritinib caps |
08.01.05 |
Formulary
|
NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer |
| Ceritinib caps |
08.01.05 |
Formulary
|
NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer |
| Certolizumab pegol injection |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Certolizumab pegol injection |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Certolizumab pegol injection |
10.01.03 |
Formulary
|
NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor |
| Certolizumab pegol injection |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Certolizumab pegol injection |
13.05.03 |
Formulary
|
NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis |
| Cetuximab injection |
08.01.05 |
Formulary
|
NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck |
| Cetuximab injection |
08.01.05 |
Formulary
|
NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck |
| Cetuximab injection |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Ciclosporin (Ikervis®) 0.1% eye drops |
11.04.02 |
Restricted Use
|
NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears |
| Cinacalcet tablets |
09.05.01.02 |
Restricted Use
|
NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy |
| Cladribine tabs |
08.02.04 |
Formulary
|
NICE TA616: Cladribine tablets for treating relapsing–remitting multiple sclerosis |
| Clomipramine caps |
04.03.01 |
Restricted Use
|
NICE CG113: Generalised anxiety disorder and panic disorder in adults: management |
| Colistimethate sodium dry powder for inhalation |
05.01.07 |
Formulary
|
NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin |
| Collagenase injection |
10.03.01 |
Restricted Use
|
NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture |
| Crizotinib caps |
08.01.05 |
Formulary
|
NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib caps |
08.01.05 |
Formulary
|
NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer |
| Crizotinib caps |
08.01.05 |
Formulary
|
NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (CDF) |
| Cubitan |
A2.03.02 |
Non Formulary
|
NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review) |
| Cytarabine and daunorubicin (liposomal) injection |
08.01.03 |
Formulary
|
NICE TA 552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia |
| Dabigatran caps |
02.08.02 |
Formulary
|
NICE TA249: Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation |
| Dabigatran caps |
02.08.02 |
Formulary
|
NICE TA157: Venous thromboembolism - dabigatran |
| Dabigatran caps |
02.08.02 |
Formulary
|
NICE TA327: Dabigatran for treatment and secondary prevention of DVT and/or PE |
| Dabrafenib caps |
08.01.05 |
Formulary
|
NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma |
| Dabrafenib caps |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Daclatasvir tabs |
05.03.03.02 |
Formulary
|
NICE TA364: Daclatasvir for treating chronic hepatitis C |
| Daclizumab injection |
08.02.04 |
Formulary
|
NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis |
| Dacomitinib caps |
08.01.05 |
Formulary
|
NICE TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Dapagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA597: Dapagliflozin with insulin for treating type 1 diabetes |
| Dapagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Dapagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes |
| Dapagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes |
| Daratumumab injection |
08.02.04 |
Formulary
|
NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma (CDF) |
| Daratumumab injection |
08.02.04 |
Formulary
|
NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma (CDF) |
| Darvadstrocel injection |
01.05 |
Non Formulary
|
NICE TA556: Darvadstrocel for treating complex perianal fistulas in Crohn’s disease |
| Dasatinib tabs |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Dasatinib tabs |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Decitabine |
08.01.03 |
Non Formulary
|
NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270) |
| Degarelix injection |
08.03.04.02 |
Formulary
|
NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA265: Bone metastases from solid tumours - denosumab |
| Denosumab |
06.06.02 |
Formulary
|
NICE TA204: Osteoporotic fractures - denosumab |
| Dexamethasone intravitreal implant |
11.08.02 |
Formulary
|
NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema |
| Dexamethasone intravitreal implant |
11.08.02 |
Formulary
|
NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema |
| Dexamethasone intravitreal implant |
11.08.02 |
Formulary
|
NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis |
| Dimethyl fumarate caps |
08.02.04 |
Formulary
|
NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis |
| Dimethyl fumarate tablets |
13.05.03 |
Formulary
|
NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis |
| Dinoprostone vaginal gel, pessaries |
07.01.01 |
Formulary
|
NICE CG70: Inducing labour |
| Docetaxel injection |
08.01.05 |
Formulary
|
NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer |
| Docetaxel injection |
08.01.05 |
Formulary
|
NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer |
| Doxorubicin hydrochloride pegylated liposomal injection |
08.01.02 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Dronedarone tabs |
02.03.02 |
Formulary
|
NICE TA197: Atrial fibrillation - dronedarone |
| Durvalumab injection |
08.01.05 |
Formulary
|
NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation (CDF) |
| Eculizumab injection |
09.01.03 |
Formulary
|
NICE HST1: Eculizumab for treating atypical haemolytic uraemic syndrome |
| Edoxaban tabs |
02.08.02 |
Formulary
|
NICE TA354: Edoxaban for treating and for preventing DVT and/or PE |
| Edoxaban tabs |
02.08.02 |
Formulary
|
NICE TA355: Edoxaban for thromboprohylaxis in non-valvular AF |
| Eltrombopag tablets |
09.01.04 |
Restricted Use
|
NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) |
| Eluxadoline tablets |
01.05 |
Formulary
|
NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea |
| Empagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes |
| Empagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes |
| Encorafenib caps |
08.01.05 |
Formulary
|
NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma |
| Entecavir tabs, oral solution |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B (incorporates TA153) |
| Entecavir tabs, oral solution |
05.03.03.01 |
Formulary
|
NICE TA153: Hepatitis B (chronic) - etecavir |
| Entrectinib caps |
08.01.05 |
Formulary
|
NICE TA644: Entrectinib for treating NTRK fusion-positive solid tumours |
| Enzalutamide caps |
08.03.04.02 |
Non Formulary
|
NICE TA580: Enzalutamide for hormone-relapsed non-metastatic prostate cancer |
| Enzalutamide tabs |
08.03.04.02 |
Formulary
|
NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated |
| Enzalutamide tabs |
08.03.04.02 |
Formulary
|
NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen |
| Epclusa® tabs |
05.03.03.02 |
Formulary
|
NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C |
| Eplerenone tabs |
02.02.03 |
Formulary
|
NICE CG172 Myocardial Infarction: cardiac rehabilitation and secondary prevention |
| Eribulin injection |
08.01.05 |
Formulary
|
NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens |
| Eribulin injection |
08.01.05 |
Non Formulary
|
NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen |
| Erlotinib tabs |
08.01.05 |
Formulary
|
NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy |
| Erlotinib tabs |
08.01.05 |
Formulary
|
NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer |
| Ertugliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA583:Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes |
| Ertugliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes |
| Etanercept |
13.05.03 |
Non Formulary
|
NICE TA103: Psoriasis - efalizumab and etanercept |
| Etanercept injection |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (NHSE) |
| Etanercept injection |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Etanercept injection |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Etanercept injection |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Etanercept injection |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Etanercept injection |
13.05.03 |
Formulary
|
NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis |
| Etelcalcetide injection |
09.05.01.02 |
Formulary
|
NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism |
| Everolimus |
08.01.05 |
Non Formulary
|
NICE TA219: Everolimus for second-line treatment of renal cell cancer |
| Everolimus tabs |
08.01.05 |
Formulary
|
NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy |
| Everolimus tabs |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Everolimus tabs |
08.01.05 |
Formulary
|
NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment |
| Everolimus tabs |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Evolocumab injection |
02.12 |
Restricted Use
|
NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia |
| Ezetimibe tabs |
02.12 |
Formulary
|
NICE TA385:Ezetimibe for primary heterozygous-familial and non-familial hypercholesterolaemia |
| Febuxostat tabs |
10.01.04 |
Formulary
|
NICE TA164: Hyperuricaemia - febuxostat |
| Finasteride tabs |
06.04.02 |
Formulary
|
NICE CG97: Lower urinary tract symptoms |
| Fingolimod caps |
08.02.04 |
Formulary
|
NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis |
| Fludarabine tabs, injection |
08.01.03 |
Formulary
|
NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia |
| Fluocinolone intravitreal implant |
11.08.02 |
Formulary
|
NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis |
| Fluocinolone intravitreal implant |
11.08.02 |
Formulary
|
NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271) |
| Fluocinolone intravitreal implant |
11.08.02 |
Formulary
|
NICE TA613: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy |
| Fremanezumab subcutaneous injection |
04.07.04.02 |
Formulary
|
NICE TA631: Fremanezumab for preventing migraine |
| Fulvestrant |
08.03.04.01 |
Non Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Fulvestrant injection |
08.03.04.01 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF) |
| Fulvestrant injection |
08.03.04.01 |
Formulary
|
NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy (CDF) |
| Fulvestrant injection |
08.03.04.01 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF) |
| Fulvestrant injection |
08.03.04.01 |
Non Formulary
|
NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer |
| Fulvestrant injection |
08.03.04.01 |
Non Formulary
|
NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer |
| Gefitinib tabs |
08.01.05 |
Formulary
|
NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer |
| Gemcitabine injection |
08.01.03 |
Formulary
|
NICE TA116: Gemcitabine for the treatment of metastatic breast cancer |
| Gemcitabine injection |
08.01.03 |
Formulary
|
NICE TA25:Guidance on the use of gemcitabine for the treatment of pancreatic cancer |
| Gemtuzumab ozogamicin infusion |
08.02.03 |
Formulary
|
NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia |
| Gilteritinib tabs |
08.01.05 |
Formulary
|
NICE TA642: Gilteritinib for treating relapsed or refractory acute myeloid leukaemia |
| Glatiramer acetate injection |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Glatiramer acetate injection |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Golimumab injection |
10.01.03 |
Formulary
|
NICE TA225: Rheumatoid arthritis - golimumab |
| Golimumab injection |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Golimumab injection |
10.01.03 |
Formulary
|
NICE TA220: Psoriatic arthritis - golimumab |
| Golimumab injection |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Golimumab injection |
10.01.03 |
Formulary
|
NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis |
| Golimumab injection |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Guselkumab injection |
13.05.03 |
Formulary
|
NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis |
| Harvoni® tabs |
05.03.03.02 |
Formulary
|
NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C |
| Holoclar |
11.99.99.99 |
Formulary
|
NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns |
| Ibrutinib caps |
08.01.05 |
Formulary
|
NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia (CDF) |
| Ibrutinib caps |
08.01.05 |
Formulary
|
NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation |
| Ibrutinib caps |
08.01.05 |
Formulary
|
NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma |
| Idelalisib tabs |
08.01.05 |
Formulary
|
NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia |
| Idelalisib tabs |
08.01.05 |
Non Formulary
|
NICE TA604: Idelalisib for treating refractory follicular lymphoma |
| Imatinib tabs |
08.01.05 |
Formulary
|
NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours |
| Imatinib tabs |
08.01.05 |
Formulary
|
NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours |
| Imatinib tabs |
08.01.05 |
Formulary
|
NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia |
| Imatinib tabs |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Imipramine tabs |
04.03.01 |
Formulary
|
NICE CG113: Generalised anxiety disorder and panic disorder in adults: management |
| Infliximab injection |
01.05.03 |
Formulary
|
NICE TA163 Infliximab for acute exacerbations of ulcerative colitis |
| Infliximab injection |
01.05.03 |
Formulary
|
NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease |
| Infliximab injection |
01.05.03 |
Formulary
|
NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy |
| Infliximab injection |
13.05.03 |
Formulary
|
NICE TA134: Infliximab for the treatment of adults with psoriasis |
| Infliximab injection |
10.01.03 |
Formulary
|
NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab |
| Infliximab injection |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Infliximab injection |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Infliximab injection |
10.01.03 |
Formulary
|
NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis |
| Inotuzumab ozogamicin injection |
08.01.05 |
Formulary
|
NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia |
| Interferon beta-1a injection |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1a injection |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Interferon beta-1b injection |
08.02.04 |
Formulary
|
NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis |
| Ipilimumab injection |
08.01.05 |
Formulary
|
NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma |
| Ipilimumab injection |
08.01.05 |
Formulary
|
NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma |
| Ipilimumab injection |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Ipilimumab injection |
08.01.05 |
Formulary
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (CDF) |
| Irinotecan Hydrochloride injection |
08.01.05 |
Formulary
|
NICE CG131: Colorectal cancer: diagnosis and management |
| Ivabradine |
02.06.03 |
Non Formulary
|
NICE CG126: Guidance on Stable Angina |
| Ivabradine |
02.06.03 |
Non Formulary
|
NICE TA267: Chronic heart failure - ivabradine |
| Ivabradine tabs |
02.06.03 |
Restricted Use
|
NICE TA267: Ivabradine for treating chronic heart failure |
| Ixazomib caps |
08.02.04 |
Formulary
|
NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF) |
| Ixekizumab injection |
13.05.03 |
Formulary
|
NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis |
| Lamivudine tabs, oral solution |
05.03.03.01 |
Formulary
|
NICE CG165: Hepatitis B |
| Lanadelumab injection |
03.04.03 |
Formulary
|
NICE TA606: Lanadelumab for preventing recurrent attacks of hereditary angioedema |
| Lapatinib |
08.01.05 |
Non Formulary
|
NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer |
| Larotrectinib oral solution |
08.01.05 |
Formulary
|
NICE TA630: Larotrectinib for treating NTRK fusion-positive solid tumours |
| Lenalidomide caps |
08.02.04 |
Formulary
|
Lenalidomide with rituximab for previously treated follicular lymphoma [TA627] |
| Lenalidomide caps |
08.02.04 |
Formulary
|
NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy |
| Lenalidomide caps |
08.02.04 |
Formulary
|
NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality |
| Lenalidomide caps |
08.02.04 |
Formulary
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Lenalidomide caps |
08.02.04 |
Formulary
|
NICE TA587: Lenalidomide plus dexamethasone for previously untreated multiple myeloma |
| Lenalidomide caps |
08.02.04 |
Formulary
|
NICE TA586: Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib |
| Lenvatinib caps |
08.01.05 |
Formulary
|
NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma |
| Lenvatinib caps |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Lenvatinib caps |
08.01.05 |
Formulary
|
NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma |
| Lesinurad tabs |
10.01.04 |
Non Formulary
|
NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout |
| Letermovir tabs, injection |
05.03.02.02 |
Formulary
|
NICE TA591: Letermovir for preventing cytomegalovirus disease after a stem cell transplant |
| Lorlatinib tabs |
08.01.05 |
Formulary
|
NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer |
| Lubiprostone capsules |
01.06.07 |
Formulary
|
NICE TA318: Lubiprostone for treating chronic idiopathic constipation |
| Lusutrombopag tabs |
09.01.04 |
Formulary
|
NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure |
| Lutetium (177Lu) oxodotreotide injection |
08.01.05 |
Formulary
|
NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours |
| Mannitol inhalation powder |
03.07 |
Formulary
|
NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266) |
| Maviret® tabs |
05.03.03.02 |
Formulary
|
NICE TA99: Glecaprevir–pibrentasvir for treating chronic hepatitis C |
| Mepolizumab injection |
03.04.02 |
Formulary
|
NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma |
| Metformin tabs |
06.01.02.02 |
Formulary
|
NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period |
| Midostaurin caps |
08.01.05 |
Formulary
|
NICE TA523: Midostaurin for untreated acute myeloid leukaemia |
| Mifamurtide |
08.02.04 |
Non Formulary
|
NICE TA154: Hepatitis B - telbivudine |
| Mifamurtide injection |
08.02.04 |
Formulary
|
NICE TA235: Mifamurtide for the treatment of osteosarcoma |
| Mirabegron m/r tabs |
07.04.02 |
Restricted Use
|
NICE TA290: Mirabegron for overactive bladder |
| Misoprostol tabs |
07.01.01 |
Formulary
|
NICE CG154: Ectopic pregnancy and miscarriage: diagnosis and initial management |
| Mycophenolate mofetil tabs, caps, suspension, injection |
08.02.01 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Mycophenolate mofetil tabs, caps, suspension, injection |
08.02.01 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Naftidrofuryl caps |
02.06.04 |
Formulary
|
NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease |
| Nalmefene tabs |
04.10.01 |
Restricted Use
|
NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence |
| Naloxegol tabs |
01.06.06 |
Formulary
|
NICE TA345 Naloxegol for treating opioid‑induced constipation |
| Naltrexone tabs |
04.10.03 |
Formulary
|
NICE TA115: Naltrexone for the management of opioid dependence |
| Naltrexone–bupropion m/r tabs |
04.05.02 |
Non Formulary
|
NICE TA494: Naltrexone–bupropion for managing overweight and obesity |
| Natalizumab injection |
08.02.04 |
Restricted Use
|
NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis |
| Necitumumab injection |
08.01.05 |
Non Formulary
|
NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer |
| Neratinib tabs |
08.01.05 |
Formulary
|
NICE TA612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab |
| Nilotinib caps |
08.01.05 |
Formulary
|
NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia |
| Nilotinib caps |
08.01.05 |
Formulary
|
NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia |
| Nintedanib caps |
08.01 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Nintedanib caps |
08.01.05 |
Formulary
|
NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer |
| Nintedanib caps |
03.11 |
Formulary
|
NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis |
| Niraparib caps |
08.01.05 |
Formulary
|
NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer (CDF) |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer (CDF) |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer (CDF) |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF) |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma (CDF) |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA558: Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (CDF) |
| Nivolumab injection |
08.01.05 |
Formulary
|
NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy |
| Nusinersen injection |
10.02 |
Formulary
|
NICE TA588: Nusinersen for treating spinal muscular atrophy |
| Obeticholic acid tabs |
01.09.01 |
Formulary
|
NICE TA443: Obeticholic acid for treating primary biliary cholangitis |
| Obinutuzumab injection |
08.02.03 |
Formulary
|
NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia |
| Obinutuzumab injection |
08.02.03 |
Formulary
|
NICE TA629: Obinutuzumab with bendamustine for treating follicular lymphoma after rituximab |
| Obinutuzumab injection |
08.02.03 |
Formulary
|
NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab |
| Obinutuzumab injection |
08.02.03 |
Formulary
|
NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma |
| Ocrelizumab injection |
08.02.04 |
Formulary
|
NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis |
| Ocrelizumab injection |
08.02.04 |
Formulary
|
NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis |
| Ocriplasmin intravitreal injection |
11.08.02 |
Formulary
|
NICE TA297: Ocriplasmin for treating vitreomacular traction |
| Ofatumumab injection |
08.02.03 |
Formulary
|
NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia |
| Olaparib tabs |
08.01.05 |
Formulary
|
NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer |
| Olaparib tabs |
08.01.05 |
Formulary
|
NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (CDF) |
| Olaratumab injection |
08.01.05 |
Formulary
|
NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma |
| Omalizumab injection |
03.04.02 |
Restricted Use
|
NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria |
| Omalizumab injection |
03.04.02 |
Restricted Use
|
NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201) |
| Orlistat caps |
04.05.01 |
Formulary
|
NICE CG189: Obesity: identification, assessment and management |
| Osimertinib tabs |
08.01.05 |
Formulary
|
NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (CDF) |
| Osimertinib tabs |
08.01.05 |
Formulary
|
NICE TA621: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Oxaliplatin injection |
08.01.05 |
Formulary
|
NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer |
| Oxaliplatin injection |
08.01.05 |
Formulary
|
NICE CG131: Colorectal cancer: diagnosis and management |
| Oxytocin injection |
07.01.01 |
Formulary
|
NICE CG70: Inducing labour |
| Paclitaxel albumin injection |
08.01.05 |
Formulary
|
NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer |
| Paclitaxel injection |
08.01.05 |
Formulary
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer |
| Paclitaxel injection |
08.01.05 |
Formulary
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer |
| Padeliporfin injection |
08.03.04.02 |
Non Formulary
|
NICE TA546: Padeliporfin for untreated localised prostate cancer |
| Palbociclib tabs |
08.01.05 |
Formulary
|
NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF) |
| Palbociclib tabs |
08.01.05 |
Formulary
|
NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Panitumumab injection |
08.01.05 |
Formulary
|
NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer |
| Panobinostat caps |
08.01.05 |
Formulary
|
NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments |
| Pazopanib tabs |
08.01.05 |
Formulary
|
NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma |
| Pegaptanib intravitreal injection |
11.08.02 |
Non Formulary
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Pegaptanib Sodium |
11.08.02 |
Non Formulary
|
NICE TA155: guidance on pegaptanib in AMD (August 2008) |
| Pegaspargase injection |
08.01.05 |
Formulary
|
NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Peginterferon Alfa |
08.02.04 |
Non Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Peginterferon alfa-2a injection |
05.03.03.01 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon alfa-2a injection |
05.03.03.01 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon alfa-2a injection |
05.03.03.01 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon alfa-2a injection |
05.03.03.01 |
Formulary
|
NICE TA96: Adefovir and peginterferon alfa-2a for the treatment of chronic hepatitis B |
| Peginterferon alfa-2b injection |
05.03.03.01 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon alfa-2b injection |
05.03.03.01 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Peginterferon alfa-2b injection |
05.03.03.01 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Peginterferon beta-1a injection |
08.02.04 |
Formulary
|
NICE TA624: Peginterferon beta-1a for treating relapsing–remitting multiple sclerosis |
| Pegylated liposomal irinotecan injection |
08.01.05 |
Non Formulary
|
NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (CDF) |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (CDF) |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF) |
| Pembrolizumab injection |
08.01.05 |
Non Formulary
|
NICE TA650: Pembrolizumab with axitinib for untreated advanced renal cell carcinoma |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA553: Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (CDF) |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (CDF) |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF) |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer |
| Pembrolizumab injection |
08.01.05 |
Formulary
|
NICE TA557: Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancer (CDF) |
| Pemetrexed injection |
08.01.03 |
Formulary
|
NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma |
| Pemetrexed injection |
08.01.03 |
Formulary
|
NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer |
| Pemetrexed injection |
08.01.03 |
Formulary
|
NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer |
| Pemetrexed injection |
08.01.03 |
Formulary
|
NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin |
| Pentosan polysulfate sodium caps |
07.04.04 |
Formulary
|
NICE TA610: Pentosan polysulfate sodium for treating bladder pain syndrome |
| Pepto-Bismol chewable tabs |
01.01 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Pertuzumab injection |
08.01.05 |
Formulary
|
NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer |
| Pertuzumab injection |
08.01.05 |
Formulary
|
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer |
| Pertuzumab injection |
08.01.05 |
Formulary
|
NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer |
| Pimecrolimus cream 1% |
13.05.03 |
Formulary
|
NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema) |
| Pirfenidone caps |
03.11 |
Formulary
|
NICE TA5004: Pirfenidone for treating idiopathic pulmonary fibrosis |
| Pixantrone injection |
08.01.02 |
Formulary
|
NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma |
| Polatuzumab vedotin injection |
08.01.05 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Pomalidomide caps |
08.02.04 |
Formulary
|
NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib |
| Ponatinib tabs |
08.01.05 |
Formulary
|
NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia |
| Prasugrel tabs |
02.09 |
Formulary
|
NICE TA317: Prasugrel with PCI for ACS (review of TA182) |
| Prucalopride tablets |
01.06.07 |
Formulary
|
NICE TA211: Constipation (women) - prucalopride |
| Raloxifene tabs |
06.04.01.01 |
Formulary
|
NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women |
| Raloxifene tabs |
06.04.01.01 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Ranibizumab intravitreal injection |
11.08.02 |
Formulary
|
NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance |
| Ranibizumab intravitreal injection |
11.08.02 |
Formulary
|
NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab |
| Ranibizumab intravitreal injection |
11.08.02 |
Formulary
|
NICE TA274: Macular oedema (diabetic) - ranibizumab |
| Ranibizumab intravitreal injection |
11.08.02 |
Formulary
|
NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration |
| Regorafenib tabs |
08.01.05 |
Formulary
|
NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib tabs |
08.01.05 |
Non Formulary
|
NICE TA514: Regorafenib for previously treated advanced hepatocellular carcinoma |
| Regorafenib tabs |
08.01.05 |
Formulary
|
NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours |
| Reslizumab injection |
03.04.02 |
Formulary
|
NICE TA479: Reslizumab for treating severe eosinophilic asthma |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA106: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA200: Hepatitis C - peginterferon alfa and ribavirin |
| Ribavirin |
05.03.05 |
Non Formulary
|
NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin |
| Ribavirin caps, tabs |
05.03.03.02 |
Formulary
|
NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C |
| Ribavirin caps, tabs |
05.03.03.02 |
Formulary
|
NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C |
| Ribavirin caps, tabs |
05.03.03.02 |
Formulary
|
NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C |
| Ribociclib tabs |
08.01.05 |
Formulary
|
NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (CDF) |
| Ribociclib tabs |
08.01.05 |
Formulary
|
NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer |
| Rifaximin tabs |
05.01.07 |
Formulary
|
NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy |
| Riluzole tabs |
04.09.03 |
Formulary
|
NICE TA20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease |
| Risankizumab injection |
13.05.03 |
Formulary
|
NICE TA596: Risankizumab for treating moderate to severe plaque psoriasis |
| Rituximab injection |
10.01.03 |
Formulary
|
NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis |
| Rituximab injection |
10.01.03 |
Formulary
|
NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor |
| Rituximab injection |
08.02.03 |
Formulary
|
NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma |
| Rituximab injection |
08.02.03 |
Formulary
|
NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia |
| Rituximab injection |
08.02.03 |
Formulary
|
NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia |
| Rituximab injection |
08.02.03 |
Formulary
|
NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma |
| Rituximab injection |
08.02.03 |
Formulary
|
NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma |
| Rituximab injection |
08.02.03 |
Formulary
|
NICE TA627: Lenalidomide with rituximab for previously treated follicular lymphoma |
| Rituximab injection |
08.02.03 |
Formulary
|
NICE TA649: Polatuzumab vedotin with rituximab and bendamustine for treating relapsed or refractory diffuse large B-cell lymphoma |
| Rivaroxaban tabs |
02.08.02 |
Formulary
|
NICE TA256: Rivaroxaban for thromboprophylaxis in AF |
| Rivaroxaban tabs |
02.08.02 |
Formulary
|
NICE TA287: Rivaroxaban for treating PE and preventing recurrent VTE |
| Rivaroxaban tabs |
02.08.02 |
Formulary
|
NICE TA261: Rivaroxaban for the treatment of DVT and prevention of recurrent DVT and/or PE |
| Rivaroxaban tabs |
02.08.02 |
Formulary
|
NICE TA607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease |
| Rivaroxaban tabs |
02.08.02 |
Formulary
|
NICE TA170: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults |
| Rivaroxaban tabs |
02.08.02 |
Formulary
|
NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of ACS |
| Roflumilast tablets |
03.03.03 |
Formulary
|
NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease |
| Romiplostim injection |
09.01.04 |
Restricted Use
|
NICE TA221: Thrombocytopenic purpura - romiplostim |
| Rucaparib tabs |
08.01.05 |
Formulary
|
NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (CDF) |
| Ruxolitinib tabs |
08.01.05 |
Formulary
|
NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis |
| Sacubitril and valsartan tabs |
02.05.05 |
Restricted Use
|
NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction |
| Sarilumab pre-filled pen or syringe |
10.01.03 |
Formulary
|
NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis |
| Secukinumab injection |
13.05.03 |
Formulary
|
NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis |
| Secukinumab injection |
10.01.03 |
Formulary
|
NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors |
| Secukinumab injection |
10.01.03 |
Formulary
|
NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs |
| Simeprevir caps |
05.03.03.02 |
Formulary
|
NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C |
| Sirolimus tabs, oral solution |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Sirolimus tabs, oral solution |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Sodium zirconium cyclosilicate suspension |
09.02.01.02 |
Formulary
|
NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia |
| Sofosbuvir tabs |
05.03.03.02 |
Formulary
|
NICE TA330: Sofosbuvir for treating chronic hepatitis C |
| Somatropin injection |
06.05.01 |
Formulary
|
NICE TA64: Growth hormone deficiency (adults) - human growth hormone |
| Somatropin injection |
06.05.01 |
Formulary
|
NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review) |
| Sorafenib |
08.01.05 |
Non Formulary
|
NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) |
| Sorafenib tablets |
08.01.05 |
Formulary
|
NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma |
| Sorafenib tablets |
08.01.05 |
Formulary
|
NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine |
| Sotagliflozin tabs |
06.01.02.03 |
Formulary
|
NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes |
| Spironolactone tabs |
02.02.03 |
Formulary
|
NICE CG127: Hypertension in adults: diagnosis and management |
| Sunitinib caps |
08.01.05 |
Formulary
|
NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours |
| Sunitinib caps |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Sunitinib caps |
08.01.05 |
Formulary
|
NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma |
| Sunitinib caps |
08.01.05 |
Formulary
|
NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease |
| Tacrolimus caps, m/r caps, injection |
08.02.02 |
Formulary
|
NICE TA481: Immunosuppressive therapy for kidney transplant in adults |
| Tacrolimus caps, m/r caps, injection |
08.02.02 |
Formulary
|
NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people |
| Tacrolimus ointment 0.03%, 0.1% |
13.05.03 |
Formulary
|
NICE TA82: Tacrolimus and pimecrolimus for atopic eczema |
| Talimogene laherparepvec injection |
08.01.05 |
Formulary
|
NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma |
| Tegafur with Uracil |
08.01.03 |
Non Formulary
|
NICE TA61: Capcitabine and tegafur - Colorectal cancer |
| Temozolomide caps |
08.01.05 |
Formulary
|
NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma |
| Temozolomide caps |
08.01.05 |
Formulary
|
NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) |
| Tenofovir disoproxil tabs |
05.03.01 |
Formulary
|
NICE CG165: Hepatitis B (chronic) - incorporates TA173 |
| Tenofovir disoproxil tabs |
05.03.01 |
Formulary
|
NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil |
| Tenofovir disoproxil tabs |
05.03.03.01 |
Formulary
|
NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B |
| Teriflunomide tablets |
08.02.04 |
Formulary
|
NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis |
| Teriparatide injection |
06.06.01 |
Formulary
|
NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women |
| Tetracycline tabs |
05.01.03 |
Formulary
|
NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management |
| Thalidomide caps |
08.02.04 |
Formulary
|
NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma |
| Ticagrelor tabs, orodispersible tabs |
02.09 |
Formulary
|
NICE TA236: Acute coronary syndromes - ticagrelor |
| Ticagrelor tabs, orodispersible tabs |
02.09 |
Formulary
|
NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction |
| Tildrakizumab injection |
13.05.03 |
Formulary
|
NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis |
| Tisagenlecleucel cells dispersion for infusion |
08.01.05 |
Formulary
|
NICE TA554: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years (CDF) |
| Tisagenlecleucel cells dispersion for infusion |
08.01.05 |
Formulary
|
NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies (CDF) |
| Tivozanib caps |
08.01.05 |
Formulary
|
NICE TA512: Tivozanib for treating advanced renal cell carcinoma |
| Tobramycin dry powder for inhalation |
05.01.04 |
Formulary
|
NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis |
| Tocilizumab injection |
10.01.03 |
Formulary
|
NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (NHSE) |
| Tocilizumab injection |
10.01.03 |
Formulary
|
NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab (NHSE) |
| Tocilizumab injection |
10.01.03 |
Formulary
|
NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198) |
| Tocilizumab injection |
10.01.03 |
Formulary
|
NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed |
| Tocilizumab subcutaneous injection |
10.01.03 |
Formulary
|
NICE TA518: Tocilizumab for treating giant cell arteritis |
| Tofacitinib tabs |
01.05.03 |
Formulary
|
NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis |
| Tofacitinib tabs |
10.01.03 |
Formulary
|
NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis |
| Tofacitinib tabs |
10.01.03 |
Formulary
|
NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs |
| Tolvaptan tabs |
06.05.02 |
Restricted Use
|
NICE TA358:Tolvaptan for treating autosomal dominant polycystic kidney disease |
| Topotecan injection |
08.01.05 |
Formulary
|
NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer |
| Topotecan injection |
08.01.05 |
Formulary
|
NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer |
| Trabectedin injection |
08.01.05 |
Formulary
|
NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma |
| Trametinib tabs |
08.01.05 |
Formulary
|
NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma |
| Trametinib tabs |
08.01.05 |
Formulary
|
NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma |
| Trastuzumab emtansine |
08.01.05 |
Non Formulary
|
NICE TA235: Osteosarcoma - mifamurtide |
| Trastuzumab emtansine injection |
08.01.05 |
Formulary
|
NICE TA632: Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer |
| Trastuzumab emtansine injection |
08.01.05 |
Formulary
|
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane |
| Trastuzumab injection |
08.01.05 |
Formulary
|
NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer |
| Trastuzumab injection |
08.01.05 |
Formulary
|
NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer |
| Treosulfan injection |
08.01.01 |
Formulary
|
NICE TA640: Treosulfan with fludarabine for malignant disease before allogeneic stem cell transplant |
| Trifluridine–tipiracil tablets |
08.01.03 |
Formulary
|
NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer |
| Ustekinumab |
13.05.03 |
Non Formulary
|
NICE TA313: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab |
13.05.03 |
Non Formulary
|
NICE TA180: Psoriasis - ustekinumab |
| Ustekinumab injection |
10.01.03 |
Formulary
|
NICE TA340: Ustekinumab for treating active psoriatic arthritis |
| Ustekinumab injection |
13.05.03 |
Formulary
|
NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis |
| Ustekinumab injection |
01.05.03 |
Formulary
|
NICE TA633: Ustekinumab for treating moderately to severely active ulcerative colitis |
| Ustekinumab injection |
01.05.03 |
Formulary
|
NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment |
| Vandetanib tabs |
08.01.05 |
Non Formulary
|
NICE TA550: Vandetanib for treating medullary thyroid cancer |
| Varenicline tabs |
04.10.02 |
Formulary
|
NICE TA123: Varenicline |
| Vedolizumab injection |
01.05.03 |
Formulary
|
NICE TA342 Vedolizumab for treating moderately to severely active ulcerative colitis |
| Vedolizumab injection |
01.05.03 |
Formulary
|
NICE TA352 Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy |
| Vemurafenib tabs |
08.01.05 |
Formulary
|
NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma |
| Venetoclax tabs |
08.01.05 |
Formulary
|
NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia (CDF) |
| Venetoclax tabs |
08.01.05 |
Formulary
|
NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia (CDF) |
| Viekirax® |
05.03.03.02 |
Formulary
|
NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C |
| Vinflunine |
08.01.04 |
Non Formulary
|
NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine |
| Vismodegib caps |
08.01.05 |
Non Formulary
|
NICE TA489: Vismodegib for treating basal cell carcinoma |
| Vortioxetine tabs |
04.03.04 |
Formulary
|
NICE CG367: Vortioxetine for treating major depressive episodes |
| Vosevi® tabs |
05.03.03.02 |
Formulary
|
NICE TA 507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
| Zepatier® tabs |
05.03.03.02 |
Formulary
|
NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C |
